Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lianhuaqingwen for treatment of Omicron variant COVID-19
ChiCTR2200057841Phase 4Recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Mar 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Lianhua Qingwen in coronavirus disease 2019 (COVID-19), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Rate of disappearance of symptoms on day 14. Started Mar 2022; status: recruiting.
02
Drugs
Lianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200057841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057841.